Canadian Society of Clinical Chemists (CSCC) consensus guidance for testing, selection and quality management of SARS-CoV-2 point-of-care tests

European Centre for Disease Prevention and Control. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. 2020:1-21. Higgins, 2020, SARS-CoV-2 nasopharyngeal swab testing-false-negative results from a pervasive anatomical misconception, JAMA Otolaryngol. Head Neck Surg., 10.1001/jamaoto.2020.2946 World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays . 2020;2020. Public Health England. SARS-CoV-2 inactivation testing: interim report . 2020. Auerswald, 2021, Assessment of inactivation procedures for SARS-CoV-2, J. Gen. Virol., 10.1099/jgv.0.001539 Hemati, 2020, Thermal inactivation of COVID-19 specimens improves RNA quality and quantity, J. Cell. Physiol. van Bockel, 2020, Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in point-of-care (POC) testing, Viruses, 12, 1208, 10.3390/v12111208 World Health Organization. Laboratory biosafety guidance related to coronavirus disease (COVID-19), Interim Guidance. 2020. Government of Canada. Hard-surface disinfectants and hand sanitizers (COVID-19): List of disinfectants with evidence for use against COVID-19 . ;2020. Government of Canada. Authorized medical devices for uses related to COVID-19: List of authorized testing devices . ;2020. Carter, 2020, Assay techniques and test development for COVID-19 diagnosis, ACS Cent. Sci., 6, 591, 10.1021/acscentsci.0c00501 Notomi, 2000, Loop-mediated isothermal amplification of DNA, Nucleic Acids Res., 28, E63, 10.1093/nar/28.12.e63 Eckbo EJ, Locher K, Caza M, Li L, Lavergne V, Charles M. Evaluation of the BioFire® COVID-19 test and Respiratory Panel 2.1 for rapid identification of SARS-CoV-2 in nasopharyngeal swab samples. Diagn Microbiol Infect Dis 2021;99:115260. Hansen, 2021, Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study, J. Clin. Microbiol., 59, 20 Visseaux, 2020, Emergency department influenza, study group. Evaluation of the QIAstat-Dx respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection, J. Clin. Microbiol., 58, 10.1128/JCM.00630-20 Share H, Zelyas N, Saxinger L, Manns B, Alberta Health Services, COVID-19 Scientific Advisory Group. COVID-19 Scientific Advisory Group Rapid Evidence Report. 2020;2021. Axell-House, 2020, The estimation of diagnostic accuracy of tests for COVID-19: a scoping review, J. Infect., 81, 681, 10.1016/j.jinf.2020.08.043 Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, Emperador D, Takwoingi Y, Cunningham J, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft L, Leeflang MMG, Spijker R, Van den Bruel A, Cochrane COVID-19 Diagnost, Test Ac, Cochrane COVID-19 Diagnostic Test, Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane database of systematic reviews 2020;2020:CD013705. Zhen W, Smith E, Manji R, Schron D, Berry GJ. Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2. J Clin Microbiol 2020;58:e00783,20. Print 2020 Jul 23. Liotti, 2020, Evaluating the newly developed BioFire COVID-19 test for SARS-CoV-2 molecular detection, Clin. Microbiol. Infect., 26, 1699, 10.1016/j.cmi.2020.07.026 Subsoontorn P, Lohitnavy M, Kongkaew C. The diagnostic accuracy of nucleic acid point-of-care tests for human coronavirus: A systematic review and meta-analysis. medRxiv 2020:338. Smithgall, 2020, Comparison of cepheid Xpert xpress and abbott ID now to roche cobas for the rapid detection of SARS-CoV-2, J. Clin. Virol., 128, 10.1016/j.jcv.2020.104428 Government of Canada. Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection;2020. Gremmels, 2021, Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection, EClinicalMedicine, 31, 10.1016/j.eclinm.2020.100677 Linares, 2020, Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms, J. Clin. Virol., 133, 10.1016/j.jcv.2020.104659 Alemany, 2021, Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test, J. Infect., 10.1016/j.jinf.2020.12.033 Brümmer L, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, Grilli M, Larmann J, Weigand M, Pollock N, Carmona S, Ongarello S, Sacks J, Denkinger C. The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. medRxiv 2021. Beck, 2021, Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients, J. Clin. Microbiol., 59, 20, 10.1128/JCM.02727-20 Iglὁi Z, Velzing J, van Beek J, van de Vijver D, Aron G, Ensing R, Benschop K, Han W, Boelsums T, Koopmans M, Geurtsvankessel C, Molenkamp R. Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal health service drive-through testing site . medRxiv 2020. Cerutti, 2020, Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2, J. Clin. Virol., 132, 10.1016/j.jcv.2020.104654 Centers for Disease Control and Prevention. Interim Guidance for Rapid Antigen Testing for SARS-CoV-2. 2020;2020. FDA. Potential for False Positive Results with Antigen Tests for Rapid Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care Providers . 2020;2020. Kucirka, 2020, Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure, Ann. Intern. Med., 173, 262, 10.7326/M20-1495 Ontario Ministry of Health. Appendix 9: Management of Individuals with Point-of-Care Testing Results. 2021:1-8. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Milind T, Mina MJ, Parker R. Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. medRxiv 2020. CDC. Guidance – Proposed Use of Point-of-Care (POC) Testing Platforms for SARS-CoV-2 (COVID-19). 2020. Canadian Public Health Laboratory Network and the Canadian Society of Clinical Chemists. Interim guidance on the use of the Abbott ID NOW™ instrument and COVID-19 assay. Can Commun Dis Rep ;46:422-6. Paltiel, 2020, Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States, JAMA Netw Open, 3, 10.1001/jamanetworkopen.2020.16818 He, 2020, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat. Med., 26, 672, 10.1038/s41591-020-0869-5 ISO 15189. Medical laboratories — Requirements for quality and competence . 2012:4.2.1(a), 4.2.1(b), 4.2.1(c), 4.2.1(d), 4.2.1(e), 4.2.1(f), 4.2.2.1(d), 4.2.2.1(e). Venner, 2020, Quality assurance practices for point of care testing programs: Recommendations by the canadian society of clinical chemists point of care testing interest group, Clin. Biochem. U.S Food and Drug Administration (FDA). SARS-CoV-2 Reference Panel Comparative Data. ;2021. Day, 2015 Caliendo, 2010, CLSI MM06: quantitative molecular methods for infectious diseases, Clin. Laborat. Standards Institute Campbell, 2020 Foundation for Innovative New Diagnostics, (FIND). Comparative evaluation of lateral flow assay tests that directly detect antigens of SARS-CoV-2. 2020. FIND Evaluation of SARS-CoV-2 Antigen Detecting Tests. 2021;2021. Fenollar, 2021, Evaluation of the panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19, J. Clin. Microbiol., 59, 20, 10.1128/JCM.02589-20 Government of Canada. COVID-19 antigen testing devices: Notice on minimum value for sensitivity . 2020;2020. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, Jó Lei WK, Tscheak P, Möncke-Buchner E, Müller MA, Krumbholz A, Drexler JF, Drosten C. Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests. 2020. Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-CoV-2 test development and validation cell: POCT evaluation of lateral flow viral antigen detection devices (LFDs) for mass community testing. 2020. Ontario Health. Quality Management Guidance for Point-of-Care Testing. 2020:1-9. Nichols, 2020, AACC guidance document on management of point-of-care testing, J. Appl. Lab. Med., 5, 762, 10.1093/jalm/jfaa059 Lippi, 2020, Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19), Clin. Chem. Lab. Med., 58, 1070, 10.1515/cclm-2020-0285 Sciacovelli, 2019, Clin. Chim. Acta, 497, 35, 10.1016/j.cca.2019.07.007 Jacobs E, Kaplanis B, DeNigro J, Beshiri A, Colby J, Dehghan M, Geaghan SM, Kampfrath T, Kirkchick H, Martin CL, Ottenbreit T, Pontius CA, Roth K, Serhir B, Skrlin S, Smith JL, St. Hill H, Thomas M, Uriona T. CLSI Essential Tools for Implementation and Management of a Point-of-Care Testing Program, 3rd Edition. Clinical and Laboratory Standards Institute 2016. Yip, 2018, Point-of-care testing: a position statement from the Canadian Society of Clinical Chemists, Clin. Biochem., 53, 156, 10.1016/j.clinbiochem.2018.01.015